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PURPOSE: To evaluate the time course and association with survival of anatomic lesion volumes and diffusion
imaging parameters for patients with newly diagnosed glioblastoma who were treated with radiation and
concurrently with either temozolomide and enzastaurin (TMZ+enza cohort) or temozolomide, erlotonib, and
bevaciumab (TMZ+erl+bev cohort). MATERIALS AND METHODS: Regions of interest corresponding to the
contrast-enhancing and hyperintense lesions on T2-weighted images were generated. Diffusion-weighted images
were processed to provide maps of apparent diffusion coefficient, fractional anisotropy, and longitudinal and radial
eigenvalues. Histograms of diffusion values were generated and summary statistics calculated. Cox proportional
hazards models were employed to assess the association of representative imaging parameters with survival with
adjustments for age, Karnofsky performance status, and extent of resection. RESULTS: Although progression-free
survival was significantly longer for the TMZ+erl+bev cohort (12.8 vs 7.3 months), there was no significant
difference in overall survival between the two populations (17.0 vs 17.8 months). The median contrast-enhancing
lesion volumes decreased from 6.3 to 1.9 cm3 from baseline to the postradiotherapy scan for patients in the
TMZ+enza cohort and from 2.8 to 0.9cm3 for the TMZ+erl+bev cohort. Changes in the T2 lesion volumes were
only significant for the latter cohort (26.5 to 11.9 cm3). The median apparent diffusion coefficient and related
diffusion parameters were significantly increased for the TMZ+enza cohort (1054 to 1225 μm2/s). More of the
anatomic parameters were associated with survival for the TMZ+enza cohort, whereas more diffusion parameters
were associated with survival for the TMZ+erl+bev cohort. CONCLUSION: The early changes in anatomic and
diffusion imaging parameters and their association with survival reflected differences in the mechanisms of action
of the treatments that were being given. This suggests that integrating diffusion metrics and anatomic lesionReceived 12 June 2015; Revised 14 September 2015; Accepted 2 October 2015
© 2015 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Translational Oncology Vol. 8, No. 6, 2015 Imaging Parameters with Newly Diagnosed Glioblastoma Wen et al. 447volumes into the Response Assessment in Neuro-Oncology criteria would assist in interpreting treatment-induced
changes and predicting outcome in patients with newly diagnosed glioblastoma who are receiving such
combination treatments.
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Glioblastoma (GBM) is the most malignant primary malignant brain
tumor in adults. The standard of care for patients with newly
diagnosed GBM consists of surgery, radiotherapy (RT), and
temozolomide (TMZ). In a recent phase III trial, patients treated
in this manner had significantly improved overall survival (OS)
compared with patients who received RT alone [1]. The median
overall survival obtained with this treatment was 15 months [1]. A
number of different therapeutic agents that are expected to have a
synergistic effect with RT and TMZ have been considered [2–6],
with the goal of improving outcomes for patients with GBM.
Assessment of early response to these combination treatments is
complicated by their different mechanisms of action and the impact
that they have on standard magnetic resonance (MR) imaging
parameters [7].
Enzastaurin is a protein kinase C β-inhibitor that is reported as
having a direct antitumor effect through the suppression of tumor cell
proliferation and induction of apoptosis, and indirect effects that are
expressed by the inhibition of tumor-induced angiogenesis [8].
Preclinical reports have shown that it is synergistic with radiation and
induces apoptosis in glioma model systems [9]. These data provided
the rationale for a recent phase II clinical trial of RT, TMZ, and
enzastaurin in patients with newly diagnosed GBM. Although the
clinical outcome data for patients from this study have already been
reported [3], the role of advanced imaging parameters in assessing
efficacy and predicting outcome has not yet been presented.
Another agent of interest for combination therapy is bevacizumab,
which is a humanized monoclonal vascular endothelial growth factor
(VEGF)–blocking antibody that normalizes vascular permeability and
regulates angiogenesis [10]. Preliminary studies of bevacizumab in
patients with recurrent GBM have shown a dramatic decrease in the
size of the enhancing lesion and an increase in progression-free
survival (PFS) [11–13]. This led to a number of clinical trials of
patients with GBM that combined bevacizumab with standard RT
and chemotherapy. The biological hypotheses that have driven these
analyses are that combination treatment would normalize tortuous
tumor vasculature, improve the delivery of chemotherapeutics, and
hence provide improved overall survival [14].
The disadvantage of treatments such as enzastaurin and bevacizumab
is that they cause changes in anatomic imaging characteristics, which
can make it difficult to use conventional methods for assessing response
to therapy. For example, agents that reduce proliferation may result in a
clinical assessment of stable disease, whereas antiangiogenic agents
decrease the size of the contrast-enhancing lesion (CEL), but this does
not necessarily signify a reduction in bulk tumor [11]. Another
complication of anti-VEGF agents that have been reported is to result in
increased tumor invasiveness that is expressed by an increase in the size
of the region of T2 hyperintensity rather than the changes in the
enhancing lesions [15]. Although the Response Assessment inNeuro-Oncology criteria include consideration of changes in the T2
lesion as part of the definition of response to therapy [16], it is not clear
whether such changes are specific to recurrent tumor or represent
nonspecific RT-induced changes in normal white matter.
Diffusion-weighted imaging has been proposed as an adjunct to
standard anatomic imaging because it can provide new information
about response to therapy through the evaluation of parametric
images that reflect variations in tissue composition and architecture
[17–19]. The most widely considered variable is the apparent
diffusion coefficient (ADC), which is sensitive to an increase in tumor
cellularity, formation of necrosis, and the presence of vasogenic
edema. Other variables of interest are the fractional anisotropy (FA),
which describes variability in the directionality of diffusion, and
eigenvalues (EV1 and EVrad), which provide information on the
magnitude of the preferred (longitudinal) direction of diffusion and
average perpendicular components. These reflect local variations in
tissue properties associated with unregulated cell growth and changes
in the extracellular environment. The hypotheses of interest are that a
decrease in FA reflects breakdown of normal brain structure and that
the magnitude of EV1 and EVRAD may be more sensitive to such
changes than the ADC alone.
Metrics describing pretreatment and early changes in diffusion
within the CEL have been reported as predictors of response to
therapy in brain tumors [17–22]. These include the evaluation of
histograms of ADC at single time points [20,21] and the functional
diffusion map (fDM), which describes changes between ADC values
on a pixel-by-pixel basis in overlapping regions of the CEL from two
successive scans [17,18]. Although these methods have been applied
to the assessment of agents such as bevacizumab [19,22], the relatively
small size of the CEL in follow-up scans means that they do not meet
the cutoff criterion of 3 to 4 cm3 that was originally defined for this
type of analysis [17,18].
The purpose of this study was to compare the patterns of early
changes in anatomic and diffusion parameters for patients with newly
diagnosed GBM who had received advanced imaging examinations
and had been participating in two different clinical trials. The
hypothesis was that the metrics considered would provide informa-
tion about the effectiveness of the treatments being considered. Scans
were obtained at baseline and at three follow-up time points. Imaging
parameters derived from these scans were evaluated to see if they were
associated with PFS and OS.
Methods
Study+ Population
A total of 75 patients with newly diagnosed GBM (WHO grade IV)
who had received advanced imaging examinations and had participated
in phase II clinical trials at UCSF were evaluated in this study. Their
diagnosis was based upon histological analysis of tissue from surgical
Table 1. Summary of Patient Characteristics for the Two Cohorts
Total #
Patients
Total #
Scans
Age Gender Extent of Resection KPS
Median
(Range)
M/F Biopsy Subtotal Gross
Total
Range
TMZ+enza 44 133 57 (25-80) 32/12 7 27 10 60-90
TMZ+erl+bev 31 103 52 (21-76) 15/16 5 17 9 60-100
448 Imaging Parameters with Newly Diagnosed Glioblastoma Wen et al. Translational Oncology Vol. 8, No. 6, 2015samples using the WHO criteria. After surgery, 44 of the patients were
treated with standard care of RT and concurrent TMZ in conjunction
with enzastaurin (TMZ+enza cohort), and 31 of the patients were
treated with erlotinib and bevacizumab (TMZ+erl+bev cohort).
Patients were required to have a Karnofsky performance score (KPS)
of ≥60 and to provide informed consent as approved by the Committee
on Human Research at UCSF. Patient characteristics were summarized
in Table 1.
The treatment schemas are represented in Figure 1 and have been
described in prior publications describing the clinical results of the trials
[3,4]. Briefly, they began within 5 weeks of diagnosis with fractionated
RT (total dose of 60 Gy) and 75 mg/m2 of TMZ given daily over a
period of 6 weeks. Patients in the TMZ+enza cohort were administered
enzastaurin (250 mg daily) concurrently with TMZ. Patients in the
TMZ+erl+bev cohort received erlotinib (patients not on antiepileptic
drugs received 150 mg/day continuously and patients on antiepileptic
drugs received 500 mg/day continuously) starting on day 1 of RT and
bevacizumab at a dose of 10 mg/kg IV every 14 days starting in week 2
of radiotherapy.MR exams considered in the analysis were performed at
four time points: following surgical resection but before RT (baseline/
pre-RT), between 3 and 5 weeks into treatment (1 month/mid-RT),
within 2 weeks after completion of RT (2 months/post-RT), and at the
next follow-up scan (4 months).
Criteria that had been used to define true progression were clinical
deterioration and/or radiological progression, which were based upon
visual assessment of changes in cross-sectional diameters of the CEL as
defined by theMcDonald criteria for the TMZ+enza cohort [23] and by
the Response Assessment in Neuro-Oncology criteria for the TMZ+
erl+bev cohort. The latter integrates changes in the T2-hyperintensity
lesion into the definition of response [16]. When tumor progression was
suspected, patients had received an additional clinical scan at a short time
interval (~1 month) to help in distinguishing true progression from
pseudoprogression.
MR Imaging and Postprocessing
A total of 239 scans were considered in the analysis, 133 from the
TMZ+enza cohort and 106 from the TMZ+erl+bev cohort. All of the
scans were obtained using a 3-T MR scanner (General Electric MedicalTMZ + enza
(n = 44)
TMZ + erl + bev
(n = 31)
BL Scan 1mth Sca
Surgical 
Resection Start of RT
Pre-RT Mid-RT
Figure 1. Treatment schemes for the twoSystems) using the body coil for transmission and an eight-channel
phased array coil for reception. The examination included axial
T2-weighted fluid attenuated inversion recovery (FLAIR) images,
volumetric T1-weighted inversion recovery spoiled gradient echo images
obtained pre- and postinjection of the contrast agent gadopentetate
dimeglumine, and six-directional axial diffusion-weighted imaging
(DWI) (b = 1000 s/mm2, number of excitations = 4) sequences.
The FLAIR and precontrast T1-weighted images were rigidly aligned
to the postcontrast T1-weighted images using previously developed
software [24]. The T2 lesions were segmented based on the
hyperintensity region of FLAIR images using a semiautomatic method
[25]. Contrast-enhancing (CE) lesions were manually defined on the
co-registered post-Gad T1 SPGR images at each available time point.
Any enhancement that was also present on the precontrast T1 images
was assumed to be indicative of acute blood products and was excluded.
To aid in performing this analysis, T1-subtraction (T1S) images were
calculated by weighting the intensities in the pre-Gad images by the
ratio of the intensities in normal-appearing white matter for the post-
versus the pre-Gad images and then subtracting them from the
corresponding post-Gad images [26]. The T1S lesion was identified by
thresholding the corresponding image within the T2 lesion at a level of
0.2 times the median intensity in normal-appearing white matter of the
postcontrast image. This threshold was chosen empirically to represent
areas that were in good visual agreement with the CEL. The resection
cavity was excluded from all regions of interest.
ADC, FA, EV1, and EVrad values were calculated on a voxel-by-voxel
basis using software that was developed in-house and based on previously
published algorithms [27]. The values obtained were related to regions
of interest on anatomical imaging by rigidly aligning the T2-weighted
(b = 0) diffusion image to the T2-weighted FLAIR and applying the
transformation to the ADCmaps. Figure 2 shows an example of the CE
and T2 lesion regions of interest superimposed upon aligned images
from baseline, mid-RT, and post-RT scans.
Statistical Analysis
The volumes of the CE, T1S, and T2 lesions were obtained by
counting the number of pixels in each region and multiplying by the
pixel dimensions. Histograms of diffusion values were obtained from
within the T2 lesion. Parameters that were used to summarize the
shape of the histograms at individual time points were the median,
10th, 25th, 75th, and 90th percentile of the distribution. The
changes in volumes and diffusion parameter values relative to the
baseline scan for subjects within each cohort were evaluated using a
Wilcoxon signed rank test. Differences in imaging parameters
between the two cohorts were evaluated using a Wilcoxon rank
sum test.n 2mths Scan
End of RT
TMZ + enza
TMZ + erl+ bev
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Figure 2. CEL (red) and T2L (green) regions of interest superimposed upon aligned T1-weighted postcontrast images from baseline,
mid-RT, and post-RT scans.
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OS and PFS were evaluated using Kaplan-Meier survival curves.
The log-rank test was used to compare the variables among patient
cohorts. OS was determined from the day of the baseline scan to the
date of death or last contact at which the patient was known to be
alive (censored). PFS was defined as the time from the baseline scan to
disease progression or death due to any cause, whichever came first.
Association of Imaging Parameters and Outcome
Cox proportional hazard models were used to evaluate which
parameters were associated with PFS or OS within each treatment0 5 10 15 20 25 30
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Figure 3. The Kaplan-Meier curves of PFS and OS for the 44 patients
cohort. Median PFS values were 7.3 months and 12.4 months, w
respectively. Log-rank tests showed that PFS was significantly long
difference in OS between the two patient cohorts.cohort. In this analysis, adjustments were made for clinical factors of
baseline KPS, age, and extent of resection (0 = biopsy, 1 = subtotal,
2 = gross total). Multivariate Cox hazard models were considered
with covariates for treatment cohort, imaging parameter, and the
interaction between treatment cohort and imaging variable. To be
considered for multivariate analysis, imaging parameters needed to
first show significance on a univariate basis. No formal adjustment of
type I error was undertaken because of the exploratory nature of the
study. P values less than .05 were considered significant. The
statistical analyses were performed with RStudio (Version 0.98.953,
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in the TMZ+enza cohort and the 31 patients in the TMZ+erl+bev
hereas median OS values were 17.8 months and 17.0 months,
er in the TMZ+erl+bev cohort but that there was no significant
Table 2. Volumes of Anatomic Regions of Interest for All Subjects
TMZ+enza Cohort TMZ+erl+bev Cohort
Timepoint Baseline 1mth 2mths 4mths Baseline 1 mth 2mths 4mths
# Subjects 39 29 38 27 29 25 25 27
T2 volume (cm3) median 20.6 22.4 18.5 17.6 26.5 24.2 10.4* 11.9*
min 3.5 4.9 3.4 4.2 1.7 2.3 0.1 0.3
max 115.9 78.8 88.3 157.9 142.3 139.2 42.8 43.5
CE volume (cm3) median 6.3 4.1* 3.3* 1.9* 2.8 1.2* 0.7* 0.2*
min 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0
max 29.6 19.1 29.5 20.8 21.9 17.6 8.7 3.5
T1Svolume (cm3) median 7.3 5.2* 4.0* 2.8* 6.3 3.7* 1.1* 0.9*
min 2.7 1.7 0.7 0.1 0.0 0.0 0.0 0.0
max 52.6 20.5 37.3 74.6 37.9 29.9 8.7 7.6
The asterisk denotes circumstances for which the change in volume from the baseline (pre-RT)
value was significant based upon a Wilcoxon signed rank test.
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Patients Characteristics and Outcomes
Age, KPS, and extent of resection were not significantly different
amongst the two patient cohorts (P N .1). Kaplan-Meier curves
describing PFS and OS are displayed in Figure 3. Median PFS was
7.3 months in the TMZ+enza cohort (95% confidence interval [CI]:
4.89-10.5 months) and 12.4 months in the TMZ+erl+bev cohort
(95% CI: 11.60-16.3 months). Median OS was 17.8 months in the
TMZ+enza cohort (95% CI: 14.0-20.5 months) and 17.0 months in
the TMZ+erl+bev cohort (95% CI: 15.9-25.1 months). Although the
PFS was significantly longer for the TMZ+erl+bev cohort (log-rank
test, P b .008), there was no significant difference in OS between the
two groups (P N .1).0
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Figure 4. Changes in CEL volume on a per patient basis for the subjec
that there was considerable variability in lesion volumes but that, in m
in size.Temporal Changes in Anatomic Lesion Volumes
Table 2 shows the changes in volumes of the T2, CE, and T1S
lesions as a function of time for the two cohorts. The majority of
patients in the TMZ+erl+bev cohort had a marked, significant
decrease in the volume of the T2 lesion from pre- to post-RT from a
median of 26.6 cm3 to 10.4 cm3 (P b .0001), whereas the patients in
the TMZ+enza cohort had median T2 volumes of 20.6 cm3 at the
pre-RT and 18.5 cm3 at the post-RT scan (P = .1645). The
reductions in the CEL volumes for the TMZ+erl+bev cohort were
from a median of 2.8 cm3 to 0.7 cm3 (P b .0001) and for the
TMZ+enza cohort from 6.3 cm3 to 3.3 cm3 (P = .0054). When
viewed as a percentage reduction, the magnitude of the decrease was
significantly larger for the TMZ+erl+bev cohort (median of −79%
versus a median of −39%; P b .001).
Figure 4 shows a representation of the variability in volumes of the
CEL on a per patient basis for subjects who had data at all four time
points. It is clear that, for many of the patients, either the initial or
follow-up CE volumes were substantially reduced in size. For the
TMZ+erl+bev cohort, the percentage of subjects with CEL volume less
than 3 cm3 at the pre-RT examwas 52%, increasing to 64%, 76%, and
89% at follow-up examinations. For the TMZ+enza cohort, the
corresponding changes were from 18% to 31%, 39%, and 59%. The
lesions were typically irregular in shape and often formed a narrow rim
around the surgical cavity. Figure 5 shows an example of the baseline
anatomic images from one such subject, together with bar graphs of the
median volumes of the CE, T2, and T1S lesions. These show the
relative sizes of the lesions and the pattern of changes at different time
points. Although the median T1S lesion volumes were slightly larger
than the manually defined CEL volumes, they showed similar patterns
of changes and were still relatively small for follow-up scans.13 14 15 16 17 18 19 20 21 22
lume per patient vs time
volume per patient vs time
13 14 15 16 17 18 19 20 21 22
4mths
2mths
1mth
base
4mths
2mths
1mth
base
ts in each cohort who had data from all four time points. This shows
any cases, volumes at follow-up scans were less than 2 to 3 cm3
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Figure 5. The images in (A) show baseline FLAIR, T1-Gad, T1, and T1S images from one subject. The bar plots in (B) show the time course
of changes in median volumes of the CE, T2, and T1S lesions for patients with all four scans. These show the differences in lesion
volumes and the patterns of changes in follow-up scans.
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image intensity parameters within regions of interest that were as
small as the CE and T1S lesion volumes, the analysis of diffusion
parameters in this study focused on values within the T2 lesion. The
median, 25th percentile, and 10th percentile ADC values within the
T2 lesion for all patients that were studied at each time point are seen
in Table 3. For the TMZ+enza cohort, there were significant increases
in ADC intensity metrics from the baseline to 1-, 2-, and 4-month
follow-up scans. Although there was a general trend toward decreasingTable 3. ADC Metrics in Units of μm2/s at Each Time Point of All Subjects With Diffusion Data
TMZ+enza Cohort
Time Point Baseline 1 Mth
# Subjects 39 29
ADC median Median 1054 1158*
Min 825 875
Max 1578 1675
ADC 25% Median 895 1015*
Min 415 755
Max 1413 1218
ADC10% Median 775 903*
Min 253 665
Max 1233 1063
Vol (ADC b 1200) in T2 lesion (cm3) Median 9.1 8.6*
Min 0.8 1.1
Max 60.2 39.9
Vol (ADC b 1000) in T2 lesion (cm3) Median 5.4 3.9*
Min 0.5 0.5
Max 43.8 26.5
Vol (ADC b 900) in T2 lesion (cm3) Median 2.7 1.8*
Min 0.2 0.2
Max 25.0 19.9
The asterix denotes circumstances for which the change in values from the baseline (pre-RT) value wADC values for the TMZ+erl+bev cohort, the changes from baseline
were not significant. These differences are clearly seen in Figure 6,
which shows an example of diffusion maps from the baseline scan in
the patient shown previously and changes in median, 25th, and 10th
percentile for patients in the two cohorts who had scans at all four
time points. Similar trends were seen for the other diffusion intensity
parameters (EV1 and EVrad).
To obtain estimates of changes in the volumes of regionswithin the T2
lesion that had low ADC values, cutoffs of 900, 1000, and 1200 μm2/sTMZ+erl+bev Cohort
2 Mths 4 Mths Baseline 1 Mth 2 Mths 4 Mths
38 27 29 25 25 27
1225* 1225* 1174 1134 1074 1044
835 925 893 1005 825 805
1755 1448 1608 1615 1918 1525
1065* 1080* 1012 985 934 934
198 835 773 875 745 705
1315 1303 1388 1375 1918 1305
945* 965* 902 875 824 835
138 765 605 698 675 595
1145 1148 1148 1135 1918 1065
7.7 6.2 7.1 14.4 6.1* 6.3*
0.6 1.2 0.6 0.4 0.6 0.3
48.4 125.4 61.7 51.1 29.4 30.4
2.2* 1.9 3.3 6.1 4.1 3.2
0.5 0.4 0.3 0.1 0.2 0.3
17.4 76.8 46.0 25.4 18.7 23.2
1.2* 1.0* 1.7 2.6 1.1 1.5
0.2 0.2 0.1 0.0 0.1 0.1
10.6 39.1 35.2 13.8 9.8 19.2
as significant based upon a Wilcoxon signed rank test.
600
700
800
900
1000
1100
1200
1300
base 1mth 2mths 4mths
median
25%
10%
600
700
800
900
1000
1100
1200
1300
base 1mth 2mths 4mths
median
25%
10%
TMZ+rel+bevTMZ+enza
FLAIRA
B
FAEVradADC
Figure 6. The baseline images (A) from the same patient as shown in Figure 5. FLAIR, ADC, EVrad, and FA. The bar plots in (B) show the
time course of changes in ADC histogram percentiles for patients with all four scans. These demonstrate that the ADC increases for the
TMZ+enza cohort and show a trend toward decreasing for the TMZ+erl+bev cohort.
Table 4. Association of Imaging Parameters with OS and PFS for Patients from the Two Cohorts at
Baseline, 1-Month (Mid-RT), 2-Month (Post-RT), and 4-Month (Follow-Up) Scans
Parameter TMZ+enza TMZ+bev
OS PFS OS PFS
Base 1 2 4 Base 1 2 4 Base 1 2 4 Base 1 2 4
T2 volume X X x
CE volume X x x x
T1S volume x X x x
Vol (ADC b 1200 in T2L) X
Vol (ADC b 1000 in T2L) x x X x
Vol (ADC b 900 in T2L) x X X X x X
25% ADC in T2L x
10% ADC in T2L X x x X
25% EVrad in T2L X
10% EVrad in T2L X x x X
“x” denotes variables that are significant when accounting for age, KPS, and EOR with P b .05, and
“X” denotes variables that were significant when accounting for age, KPS, and EOR with P b .01.
The diffusion metrics were obtained by analysis of intensities of the ADC and radial diffusivity
(EVrad) within the T2 lesion (T2l).
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volume parameters at follow-up examinations, with the change from
baseline being significant for all ADC levels at the mid-RT exam, for the
volumeswithADCb1000 andADCb900 at the post-RT exam, and for
the volumes with ADC b900 at the 4-month follow-up exam. For the
TMZ+erl+bev cohort, only the reduction in volumes in the T2 lesion
with ADC b1200 were significant from baseline to post-RT and from
baseline to the 4-month follow-up exam.
Association of Imaging Parameters and Outcome
Table 4 summarizes the Cox proportional hazard analysis of
associations between imaging parameters and patient outcomes (PFS
and OS) at the baseline and follow-up scans, with the commonly
considered clinical factors of age, KPS, and extent of resection being
considered as covariates. Clearly, there were more anatomic variables
associated with outcome for the TMZ+enza cohort and more diffusion
parameters associated with outcome for the TMZ+erl+bev cohort. Of
particular note is that the volumes of the T2, CE, and T1S lesion at
the 2-month (post-RT) scan were all found to be associated with OS
(P = .0012, .0092, and .0099, respectively) and PFS (P = .0076, .016,
and .024, respectively) in the TMZ+enza cohort. The only anatomic
volume parameters associated with outcome for the TMZ+erl+bev
cohort were the CEL at the 1-month scan for OS (P = .039) and at the
2-month scan for PFS (P = .025).
The only diffusion parameters associated with outcome for the
TMZ+enza cohort were the volumes of regions with low ADC values
at 1-month scan for OS (P = .026) and at 2-month scan for PFS
(P = .042). For the TMZ+erl+bev cohort, all of the volumetric diffusion
parameters were associated with OS at the 4-month scan with very low
P values (P = .000042, .00056, and .0065), whereas the volume withADC b900 in the T2 lesion was also associated with OS at
1-month (P = .0019) and 2-month (P = .0015) scans. Similar
trends were seen for these parameters with PFS, but the
significance levels were lower. The time point at which diffusion
intensity parameters were associated with outcome was the
2-month scan for OS (P = .007 for ADC and P = .00053 for
EVrad) and PFS (P = .0021 for ADC and P = .0011 for EVrad). The
10th percentile values of the ADC and EVrad were also associated with
PFS at baseline and 1-month scans.
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This study performed a retrospective analysis of patients who had
received advanced MR imaging examinations and had been treated on
two different clinical protocols that combined novel therapeutics with
involved radiation and TMZ. Although the patients with appropriate
imaging data were subsets of the total population in each of the
therapeutic trials, their demographics, PFS, and OS were represen-
tative of the results from the clinical evaluation of treatment
effectiveness [2,3]. In particular, there was a significant difference
in PFS between the cohort that received combination therapy with
RT, TMZ, erlotinib, and bevacizumab compared with the cohort that
received RT, TMZ, and enzastaurin; there was no difference in OS.
This observation is consistent with reports from other recent
multi-institutional phase III trials of patients with newly diagnosed
GBM who received combination therapy that included bevacizumab
[4,5]. Factors that may contribute to the prolonged PFS for this
patient cohort are changes in permeability of the blood-brain barrier
that are expressed by a reduction in the volume of the CE but do not
necessarily correspond to a decrease in the number of tumor cells [11].
The latter is commonly referred to as “pseudoresponse” [28,29] and
compromises the use of changes in the CE for predicting treatment
efficacy [16,30]. Although bevacizumab and enzastaurin are both
thought to have an impact upon angiogenesis, their mechanisms of
action are different, and it is not surprising that the patterns of changes
in imaging parameters are different for the two cohorts.
As a protein kinase C β-inhibitor, enzastaurin is thought to not
only impact angiogenesis but also reduce proliferation and increase
apoptosis [8,9]. Whereas the link between changes in vessel
permeability and contrast-enhanced T1-weighted imaging is well
understood, it is not clear how changes in proliferation and apoptosis
would be expressed in terms of alterations in imaging parameters. For
the cohort of patients treated with enzastaurin, the significant
reductions in the volume of the CE and T1S lesions can be directly
linked to changes in vessel permeability. Alterations in the volume of
T2 lesion were more variable and did not reach statistical significance
for the population as a whole. Of interest is that the volumes of all
three anatomic lesions that were observed at the 2-month (post-RT)
exam were associated with PFS and OS, indicating that there is a
direct link between anatomic imaging parameters and tumor burden
at this time point.
The increase in ADC and other diffusion parameters that are
observed for this cohort of patients at their follow-up scans is
consistent with changes in the extracellular environment caused by
increased apoptosis, gliosis, and formation of edema. Although these
changes do reflect treatment effects, it appears that they act to mask
the relationship between ADC and tumor cellularity and result in very
few of the diffusion metrics from these time points being associated
with outcome. Taken together, the anatomic and diffusion
observations suggest that, although there is an effect of enzastaurin
on the vessel permeability, the factors that dominate outcome are its
antitumor effects on proliferation and apoptosis, which in combina-
tion with RT and TMZ are able to directly impact tumor burden.
As a humanized monoclonal VEGF-blocking antibody, bevaziumab
has been shown to act on GBM by inhibiting angiogenesis, which has
been shown to decrease vascular permeability and reduce the amount of
edema through a steroidlike effect [13]. Erlotinib is a tyrosine kinase
inhibitor, which acts on epidermal growth factor. When applied in
combination with RT and TMZ in a prior clinical trial of patients with
newly diagnosed GBM, it was well tolerated but did not confer asurvival advantage [2]. Of interest from our study is that, although
dramatic early effects of bevacizumab on the volumes of anatomic
lesions were clearly seen, there was only a weak association for CEL
volume with outcome, and neither the T1S nor T2 lesion volumes were
associated with OS or PFS for this patient cohort. This suggests that the
early changes in anatomic lesion volumes are secondary effects of the
treatments being given and are not representative of changes in tumor
burden. Although the reduction in volume of the T2 lesion may have a
positive impact on quality of life by reducing the need for additional
steroids, it does not appear to prolong survival.
One of the difficulties in using early changes in the volume of the
CEL to assess antiangiogenic effects for patients with newly diagnosed
GBM is that the volumes considered may be too small to provide
reliable parameter estimates. The policy at our institution is to
perform maximal safe resection, which means that 30% to 50% of the
patients are assessed as having a gross total resection of their
enhancing lesion. Although there may be some tumor growth before
RT, this means that many of the baseline and follow-up scans either
do not enhance or have relatively small enhancing volumes. This
problem is accentuated for cases where there are reductions in vessel
permeability during treatment. For the cohort treated with
bevacizumab in our study, the majority of lesions had a CEL volume
at the post-RT exam that was less than 1 cm3, and a third of the
patients had nonenhancing progressive disease. This provides strong
motivation for using diffusion imaging parameters to detect
biologically relevant changes in the nonenhancing T2.
Parameters that have been proposed as early biomarkers for
assessing response to therapy are based upon the histogram analysis of
ADC values in the CEL and the manner in which these parameters
change before and during treatment [20,21,31] The fDM and its
derivatives, such as sfDM maps [32], register serial images and then
examine pixel-by-pixel correlations within specific regions of interest
for two or more examinations. This has been shown to provide
relevant information for evaluation of changes in ADC within the
CEL between baseline and 1-month follow-up scans for cases where
the overlapping lesion volumes on registered images are greater than
3 mlcc in size. As can be seen from our results, using this cutoff would
exclude the majority of our patients from being evaluated. A further
issue has been that there is often a large surgical cavity in the baseline
exam that shrinks over the next few months and can make it difficult
to perform accurate registration between these early scans. Although
nonrigid image registration may help to ease this problem [33], the
issue of dealing with small lesion volumes still needs to be addressed.
For our study, we focused the analysis on variations in diffusion
parameters within the relatively larger T2 lesion and did not require
the analysis of overlap in serial examinations.
As can be seen from the results from the cohort of patients treated
with enzastaurin, the patterns of changes in volumes and diffusion
parameters within the T2 lesion are determined by a combination of
factors that can make it difficult to interpret whether the treatment
has had a positive or negative effect. Infiltrative tumor and vasogenic
edema are both commonly present in portions of the lesion but may
have opposing effects within the tumor microenvironment
[34,35,12]. For tumors that are being treated with bevacizumab,
we observed that the anti-VEGF effect leads to more effective control
of vasogenic edema, a significant reduction in the volume of the T2
lesion, and a trend toward reduction in ADC and other diffusion
values. This is consistent with prior studies of such agents [20,21].
Our results suggest that the reduction in edema observed with
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cellularity and the observed diffusion metrics. This results in a large
number of metrics that described low ADC and EVrad values in the
T2 lesion being significant risk factors for PFS and OS.
One of the complications in visual interpretation of diffusion images
is that many of the metrics highlighted by our analysis correspond to
regions within the anatomic lesion that have ADC values of 1000 or
less. This means that their intensities on ADC maps are close to the
values in normal-appearing white matter and that it may be difficult to
make a reliable assessment of tumor boundaries. Defining regions of
interest based upon the anatomic lesion, generating histograms of
diffusion parameters within the region, and deriving summary statistics
that describe the size and shape of the histogram gave objective criteria
for assessing response to therapy and predicting survival.
Although the time points and diffusion metrics considered here
have strong associations with survival for the patients who were
receiving bevacizumab, caution should be taken in interpreting ADC
values at other time points. In postoperative images, low ADC values
that are due to ischemia effects may be observed. Although these
effects typically return to normal within 90 days [36], they may
explain why the baseline ADC parameters were not associated with
survival in our study. Another issue that can confound the
interpretation of low ADC is the formation of gelationous necrosis,
which was an indication of response to therapy. This may occur in
patients who are treated with bevacizumab but typically not until
several months after RT [37–41].
Conclusions
This study evaluated 75 patients with newly diagnosed GBM and
found differences in the patterns of early changes in imaging
parameters that were associated with the mechanism of action of the
agents being given. For patients treated with enzastaurin, the
reduction in volume of the CE and T1S lesions, together with the
association of post-RT lesion volumes with OS and PFS, suggests that
there is a direct impact of the treatment upon tumor burden. This
may be due to the antiproliferative effect of enzastaurin itself or to the
synergistic effects of RT and TMZ. The situation is more complex for
diffusion parameters, as the relationship between tumor cellularity
and ADC was confounded by tissue disruption and edema. For
patients treated with bevacizumab, the anti-VEGF effect was
expressed by reductions in the volumes of the anatomic lesions, but
these did not have a direct link with alterations in tumor burden.
Despite this observation, the antisteroid effect of bevacizumab was a
positive factor in that it appeared to unmask the relationship of
diffusion parameters and tumor cellularity. This resulted in metrics
such as the volume of regions having low ADC values at follow-up
scans and the 10th or 25th percentile of ADC or EVrad values within
the T2 lesion being strongly associated with survival. In considering
the results obtained from these two patient cohorts, it is clear that
interpretation of early changes in the size of anatomic lesions should
consider the mechanism of action of the treatment regimen being
used and that metrics derived from diffusion imaging can be very
helpful in assessing how such changes may impact clinical outcome.
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